{"id":"https://openalex.org/W2556920708","doi":"https://doi.org/10.1182/blood.v114.22.954.954","title":"Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.","display_name":"Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2556920708","doi":"https://doi.org/10.1182/blood.v114.22.954.954","mag":"2556920708"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.954.954","doi":"https://doi.org/10.1182/blood.v114.22.954.954","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.954.954","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065898212","display_name":"Jana Jakub\u0131\u0301kov\u00e1","orcid":"https://orcid.org/0000-0003-2593-569X","observed_orcids":["https://orcid.org/0000-0003-2593-569X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jana Jakubikova","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045679042","display_name":"David N. Cervi","orcid":"https://orcid.org/0000-0003-0595-4834","observed_orcids":["https://orcid.org/0000-0003-0595-4834"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David N. Cervi","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113640739","display_name":"John F. Daley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"John F. Daley","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050423489","display_name":"Dana Cholujov\u00e1","orcid":"https://orcid.org/0000-0003-4024-7713","observed_orcids":["https://orcid.org/0000-0003-4024-7713"]},"institutions":[{"id":"https://openalex.org/I4210121077","display_name":"Cancer Research Institute of the Slovak Academy of Sciences","ror":"https://ror.org/02v8wkr26","country_code":"SK","type":"facility","lineage":["https://openalex.org/I207624831","https://openalex.org/I4210121077","https://openalex.org/I4210123996"]}],"countries":["SK"],"is_corresponding":true,"raw_author_name":"Danka Cholujova","raw_affiliation_strings":["Tumor Immunology, Cancer Research Institute, Bratislava, Slovak Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tumor Immunology, Cancer Research Institute, Bratislava, Slovak Republic","institution_ids":["https://openalex.org/I4210121077"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006357976","display_name":"Melissa Gaik Ming Ooi","orcid":"https://orcid.org/0000-0002-7392-0655","observed_orcids":["https://orcid.org/0000-0002-7392-0655"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Melissa G. Ooi","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069524712","display_name":"Steffen Klippel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Steffen Klippel","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054816287","display_name":"Simona Blotta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simona Blotta","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004321069","display_name":"Merav Leiba","orcid":"https://orcid.org/0000-0002-3410-8496","observed_orcids":["https://orcid.org/0000-0002-3410-8496"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Merav Leiba","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091354090","display_name":"Jake E. Delmore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jake Delmore","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115591881","display_name":"Douglas W. McMillin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Douglas McMillin","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018522443","display_name":"Efstathios Kastritis","orcid":"https://orcid.org/0000-0001-8191-5832","observed_orcids":["https://orcid.org/0000-0001-8191-5832"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Efstathios Kastritis","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049711954","display_name":"Jacob P. Laubach","orcid":"https://orcid.org/0000-0001-7565-2052","observed_orcids":["https://orcid.org/0000-0001-7565-2052"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jacob Laubach","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Paul Richardson","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113831431","display_name":"J\u00e1n Sedl\u00e1k","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121077","display_name":"Cancer Research Institute of the Slovak Academy of Sciences","ror":"https://ror.org/02v8wkr26","country_code":"SK","type":"facility","lineage":["https://openalex.org/I207624831","https://openalex.org/I4210121077","https://openalex.org/I4210123996"]}],"countries":["SK"],"is_corresponding":true,"raw_author_name":"Jan Sedlak","raw_affiliation_strings":["Tumor Immunology, Cancer Research Institute, Bratislava, Slovak Republic"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tumor Immunology, Cancer Research Institute, Bratislava, Slovak Republic","institution_ids":["https://openalex.org/I4210121077"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth C. Anderson","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012712111","display_name":"Constantine S. Mitsiades","orcid":"https://orcid.org/0000-0003-2321-8005","observed_orcids":["https://orcid.org/0000-0003-2321-8005"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Constantine S. Mitsiades","raw_affiliation_strings":["Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5004321069","https://openalex.org/A5006357976","https://openalex.org/A5018522443","https://openalex.org/A5043526996","https://openalex.org/A5045679042","https://openalex.org/A5049711954","https://openalex.org/A5050423489","https://openalex.org/A5065898212","https://openalex.org/A5069524712","https://openalex.org/A5091354090","https://openalex.org/A5113640739","https://openalex.org/A5113831431","https://openalex.org/A5115591881"],"corresponding_institution_ids":["https://openalex.org/I4210117453","https://openalex.org/I4210121077"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.37693176,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":95},"biblio":{"volume":"114","issue":"22","first_page":"954","last_page":"954"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10336","display_name":"Cancer Cells and Metastasis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10345","display_name":"Hematopoietic Stem Cell Transplantation","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":1.0},{"id":"https://openalex.org/keywords/immunomodulators","display_name":"immunomodulators","score":0.968999981880188},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/thalidomide-derivatives","display_name":"thalidomide derivatives","score":0.8199999928474426},{"id":"https://openalex.org/keywords/abcg2","display_name":"ABCG2","score":0.9520000219345093},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5960000157356262},{"id":"https://openalex.org/keywords/mesenchymal-stem-cells","display_name":"mesenchymal stem cells","score":0.8569999933242798},{"id":"https://openalex.org/keywords/bone-marrow-microenvironment","display_name":"bone marrow microenvironment","score":0.7649999856948853},{"id":"https://openalex.org/keywords/syndecan-1","display_name":"syndecan-1","score":0.7229999899864197},{"id":"https://openalex.org/keywords/stem-like-cells","display_name":"stem-like cells","score":0.6050000190734863},{"id":"https://openalex.org/keywords/signaling-pathways","display_name":"signaling pathways","score":0.5249999761581421},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.42899999022483826},{"id":"https://openalex.org/keywords/cell-proliferation","display_name":"cell proliferation","score":0.3179999887943268},{"id":"https://openalex.org/keywords/cfu-assay","display_name":"CFU assay","score":0.46799999475479126},{"id":"https://openalex.org/keywords/hoechst-33342","display_name":"Hoechst 33342","score":0.9010000228881836}],"concepts":[{"id":"https://openalex.org/C2780546549","wikidata":"https://www.wikidata.org/wiki/Q7508338","display_name":"Side population","level":4,"score":0.8293064832687378},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.6759599447250366},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6734092235565186},{"id":"https://openalex.org/C16930146","wikidata":"https://www.wikidata.org/wiki/Q4381253","display_name":"Stromal cell","level":2,"score":0.6364555358886719},{"id":"https://openalex.org/C117262875","wikidata":"https://www.wikidata.org/wiki/Q5135057","display_name":"Clonogenic assay","level":3,"score":0.6308847665786743},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5457444190979004},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4917583763599396},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.4766160547733307},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.4654805064201355},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4480411112308502},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.41311895847320557},{"id":"https://openalex.org/C55427017","wikidata":"https://www.wikidata.org/wiki/Q1638475","display_name":"Cancer stem cell","level":3,"score":0.2861735224723816},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.24469631910324097},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.2105560302734375},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09052437543869019},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.954.954","doi":"https://doi.org/10.1182/blood.v114.22.954.954","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.954.954","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9789000153541565}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2536618980","https://openalex.org/W1996349127","https://openalex.org/W2979767769","https://openalex.org/W2559333756","https://openalex.org/W2267289162","https://openalex.org/W2907354992","https://openalex.org/W2587247178","https://openalex.org/W1996907841","https://openalex.org/W1935996759","https://openalex.org/W1546547645"],"abstract_inverted_index":{"Abstract":[0,1],"954":[2],"Introduction:":[3],"Multiple":[4],"myeloma":[5],"(MM),":[6],"a":[7,34,45,83,119,176,187,291,328,487],"malignancy":[8],"of":[9,26,37,44,49,82,121,133,144,157,207,237,247,258,268,283,294,319,331,340,349,366,375,432,442,457,464,469,514,525,547,566],"plasma":[10],"cells,":[11,51,270],"remains":[12],"incurable":[13],"even":[14],"though":[15],"newly":[16],"established":[17],"regimens":[18],"incorporating":[19],"conventional":[20],"and":[21,30,60,78,97,140,149,160,174,256,281,315,317,352,399,401,407,435,494,501],"novel":[22],"agents":[23],"are":[24,519],"capable":[25],"achieving":[27],"complete":[28],"clinical":[29],"biochemical":[31],"remissions":[32],"in":[33,80,94,118,130,136,171,210,296,300,306,412,429,449],"sizeable":[35],"subset":[36],"MM":[38,50,81,123,200,332,414,424,443,470],"patients.":[39],"This":[40,286],"indicates":[41],"the":[42,76,115,131,142,158,166,179,238,245,266,271,279,323,338,347,430,454,462,479,523],"presence":[43],"distinctive":[46],"drug-resistant":[47],"sub-population":[48],"which":[52,90,409],"might":[53],"be":[54],"responsible":[55],"for":[56],"tumor":[57,516],"re-growth.":[58],"Methods":[59],"Results:":[61],"To":[62],"evaluate":[63,75],"this":[64,372,515],"phenomenon,":[65],"we":[66,336,388],"performed":[67,107],"flow":[68,108],"cytometry-based":[69],"Hoechst":[70],"33342":[71],"staining":[72],"assay":[73],"to":[74,101,113,168,192,216,357,420,498,522,529],"existence":[77],"characteristics":[79],"population":[84,88,117,177,456,518],"known":[85,239],"as":[86,361,363,405,446,448],"side":[87],"(SP),":[89],"has":[91,98],"been":[92,99],"identified":[93,389],"diverse":[95,297],"neoplasias":[96],"reported":[100],"exhibit":[102],"\u201cstem-like\u201d":[103],"features.":[104],"We":[105,152,195],"specifically":[106],"cytometry":[109],"or":[110,423,549,568],"ImageStream":[111],"analyses":[112,127],"quantify":[114],"SP":[116,134,150,159,163,184,213,231,248,284,301,350,367,381,458,492],"panel":[120],"18":[122],"cell":[124,138,333,382,517],"lines.":[125],"These":[126],"revealed":[128],"heterogeneity":[129],"proportion":[132],"fractions":[135],"different":[137,499],"lines":[139,202],"indicated":[141],"lack":[143],"correlation":[145],"between":[146],"CD138":[147],"expression":[148],"fraction.":[151],"observed":[153,197,353],"that,":[154],"after":[155,439],"sorting":[156],"non-SP":[161,193,218,269],"fractions,":[162],"cells":[164,185,201,232,302,344,351,377,415,418,425,444,459,471,493],"have":[165],"potential":[167,365],"generate":[169],"colonies":[170],"CFU":[172],"assays,":[173,229],"regenerate":[175],"resembling":[178],"original,":[180],"pre-sorted,":[181],"one.":[182],"Moreover,":[183],"had":[186],"high":[188],"proliferation":[189,364],"index":[190],"compared":[191,215,419],"cells.":[194,219,285,368],"also":[196],"that":[198,261,354,482,489,511],"most":[199],"express":[203],"significantly":[204,277,379],"higher":[205],"levels":[206],"ABCG2":[208,240,251],"transcripts":[209],"their":[211,217,496],"sorted":[212],"fraction":[214],"The":[220],"mRNA":[221],"profile":[222],"results":[223],"were":[224,410],"further":[225,512],"corroborated":[226],"by":[227,290,378],"functional":[228],"where":[230],"showed":[233],"more":[234],"pronounced":[235],"efflux":[236],"substrate":[241],"mitoxantrone,":[242],"consistent":[243],"with":[244,250,416,472],"association":[246],"phenotype":[249],"expression.":[252],"Interestingly,":[253,369],"at":[254],"concentrations":[255],"durations":[257],"drug":[259,473],"exposure":[260],"did":[262],"not":[263],"substantially":[264],"affect":[265],"viability":[267],"immunomodulatory":[272],"thalidomide":[273],"derivative":[274],"(IMiDs)":[275],"lenalidomide":[276],"decreased":[278],"percentage":[280],"clonogenicity":[282],"response":[287],"was":[288,437],"accompanied":[289],"distinct":[292],"pattern":[293],"changes":[295,305],"signaling":[298],"pathways":[299],"(including":[303],"phosphorylation":[304],"Akt,":[307],"GSK-3a/b,":[308],"MEK1,":[309],"c-Jun,":[310],"p53,":[311],"p38":[312],"MAPK,":[313],"p70S6K":[314],"STAT3)":[316],"increase":[318],"CD138-/low+":[320],"phenotype.":[321],"Because":[322],"BM":[324],"microenvironment":[325],"is":[326],"considered":[327],"key":[329],"regulator":[330],"biological":[334],"behavior,":[335],"evaluated":[337],"impact":[339],"bone":[341],"marrow":[342],"stromal":[343,376,417],"(BMSCs)":[345],"on":[346,543,562],"behavior":[348],"BMSCs":[355],"led":[356],"increased":[358],"percentage,":[359],"viability,":[360],"well":[362,447],"IMiDs":[370,483],"abrogated":[371],"stimulatory":[373],"effect":[374],"decreasing":[380],"percentages.":[383],"In":[384,506],"these":[385,433],"co-culture":[386,413,450],"models,":[387],"several":[390],"cytokines,":[391],"including":[392],"IL-1b,":[393],"IL-10,":[394],"IL-17;":[395],"chemokines":[396,436],"(MIP-1a,":[397],"MIP-1b":[398],"IP-10)":[400],"growth":[402],"factors":[403],"such":[404,486],"GM-CSF":[406],"VEGF,":[408],"up-regulated":[411],"stroma":[421],"alone":[422],"alone.":[426],"Significant":[427],"modulation":[428],"production":[431],"cytokines":[434],"detected":[438],"IMiD":[440],"treatment":[441],"only,":[445],"model.":[451],"Conclusion:":[452],"Identifying":[453],"clonogenic":[455],"could":[460,484],"facilitate":[461],"development":[463],"new":[465,527],"strategies":[466,528],"targeting":[467],"subpopulations":[468],"resistant":[474],"properties.":[475],"Our":[476],"study":[477],"raises":[478],"intriguing":[480],"possibility":[481],"represent":[485],"strategy":[488],"can":[490],"target":[491],"counteract":[495],"resistance":[497],"conventional,":[500],"perhaps":[502],"some":[503],"novel,":[504],"therapies.":[505],"addition,":[507],"our":[508],"data":[509],"suggest":[510],"studies":[513],"warranted":[520],"towards":[521],"goal":[524],"developing":[526],"treat":[530],"MM.":[531],"Disclosures:":[532],"Laubach:":[533],"Novartis:":[534],"Consultancy,":[535,574,579,584,589,593,598,602,606,609],"Honoraria.":[536],"Richardson:Millenium:":[537],"(Speakers'":[538,557],"bureau":[539,558],"until":[540,559],"7/1/09),":[541,560],"Membership":[542,561],"an":[544,563],"entity's":[545,564],"Board":[546,565],"Directors":[548,567],"advisory":[550,569],"committees,":[551,570],"Research":[552,576,581,586,616,620,625,629],"Funding,":[553],"Speakers":[554,571],"Bureau;":[555],"Celgene:":[556,583],"Bureau.":[572],"Anderson:Novartis:":[573],"Honoraria,":[575,580,585],"Funding;":[577,582,617,621,626],"Millennium:":[578],"Funding.":[587,630],"Mitsiades:Millennium:":[588],"Honoraria;":[590,594,599,603,607,610],"Novartis":[591],":":[592,597,624],"Bristol-Myers":[595],"Squibb":[596],"Merck":[600],"&Co:":[601],"Kosan":[604],"Pharmaceuticals:":[605,628],"Pharmion:":[608],"PharmaMar:":[611],"Patents":[612],"&":[613],"Royalties;":[614],"Amgen:":[615],"AVEO":[618],"Pharma:":[619],"EMD":[622],"Serono":[623],"Sunesis":[627]},"counts_by_year":[{"year":2021,"cited_by_count":2}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-11-30T00:00:00"}